Investigator Names and Contact Information
Core study approved by WHI Steering Committee
The WHI hormone trials were designed to evaluate the hypothesis that postmenopausal hormone therapy would reduce coronary heart disease risk. The E alone trial was stopped on March 1, 2004 and preliminary data indicate no increase or decrease in risk of CHD over the trial duration; however, there was a modest and non-significant increase in risk in the first two years balanced by a possible risk reduction in the final years. In contrast to the findings for the E+P trial, in the E alone trial there was a trend towards lower risk of breast cancer. There was an increase in risk for stroke of about the same magnitude in both trials. The study group is committed to trying to understand the pathophysiologic basis for the variation in risk of these diseases with the use of E+P and E-alone, as well as contributing to the overall understanding of the genetics of these diseases.